G20.B2

🧬 ICD-10-CM G20.B2 — Parkinson’s Disease With Dyskinesia, With Fluctuations

Billable Code Confirmed

ICD-10-CM G20.B2 is a valid, billable 5-character alphanumeric ICD-10-CM code for FY2026. All five characters are present: G20 (category — Parkinson’s Disease) + .B (with dyskinesia) + 2 (with fluctuations/OFF episodes). No 7th character is required. Introduced effective October 1, 2023 (FY2024) as the most advanced motor complication subcode in the G20 subcategory expansion that replaced the retired single G20 code.

Non-Billable Parent Codes — Never Submit These

• ❌ G20 — Retired 3-character code; non-billable since FY2024; generates a coding specificity rejection
• ❌ G20.B — 4-character header — non-billable; missing fluctuation specifier

Always submit G20.B2 (all 5 characters) when Parkinson’s disease with both dyskinesia AND documented motor fluctuations or OFF episodes is the diagnosis. G20.B2 is the most clinically complex of all G20 subcodes and should be selected only when both complications are explicitly documented.

Two Conditions Both Required — G20.B2 Requires Both Dyskinesia AND Fluctuations

G20.B2 sits at the intersection of the two G20 motor complication axes and requires explicit physician documentation of BOTH:

• Dyskinesia — involuntary, purposeless choreiform/choreoathetoid movements from long-term levodopa dopamine receptor hypersensitization; per AHA Coding Clinic Q1 2024, physician must specifically document “dyskinesia,” “LID,” or equivalent — “tremor” alone does NOT qualify for G20.B coding
• Fluctuations / OFF episodes — wearing-off, end-of-dose deterioration, early-morning akinesia, unpredictable ON-OFF switching; per the March 2026 Coding Clinic Alphabetic Index update, “OFF episodes” is an explicit cross-reference to fluctuations

If only dyskinesia is documented → G20.B1 If only wearing-off/OFF episodes are documented → G20.A2 If both are documented → G20.B2 ← this code

Code Classification

ICD-10-CM Diagnosis Code — Etiology code. G20.B2 sequences FIRST when Parkinson’s disease dementia is also coded — the F02.x dementia codes are mandatory manifestation codes that always sequence second per the etiology/manifestation convention. For associated inpatient procedure coding, see the ICD-10-PCS Crosswalk section below.

---

🔍 Code Description

ICD-10-CM G20.B2 classifies idiopathic Parkinson’s disease at its most advanced motor complication stage, characterized by the simultaneous presence of both levodopa-induced dyskinesia (LID) and motor fluctuations (wearing-off / OFF episodes) — the two cardinal long-term complications of dopaminergic therapy that together define advanced Parkinson’s disease from a motor standpoint.

At the G20.B2 stage, the dopaminergic nigrostriatal pathway has undergone sufficient neurodegeneration that the therapeutic window for oral levodopa has become critically and simultaneously narrow in two directions: peak-dose stimulation produces dyskinesia (excess involuntary movements from receptor hypersensitization) while trough-level insufficiency produces OFF periods (return of bradykinesia, rigidity, and tremor as plasma levodopa falls). The patient is trapped in a pharmacological squeeze between disabling involuntary movements at peak and disabling parkinsonian symptoms at trough — with a very narrow, often brief window of acceptable ON time with manageable dyskinesia in between.

This dual-complication state — the coexistence of dyskinesia AND wearing-off — affects approximately 40-70% of patients with Parkinson’s disease after 5-9 years of levodopa therapy and represents the primary clinical indication for all three major advanced device-assisted therapies: deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG/CLES), and continuous subcutaneous apomorphine infusion (CSAI). Standard oral regimen optimization alone — dose fractionation, COMT inhibitors, MAO-B inhibitors, dopamine agonists — is generally insufficient to adequately manage both complications simultaneously at this stage, making G20.B2 the strongest ICD-10-CM code supporting advanced therapy medical necessity across all G20 subcodes.

---

🌳 Code Tree / Hierarchy

G20-G26 Extrapyramidal and Movement Disorders  
│  
├── G20 — Parkinson's Disease ❌ Non-billable (retired as of FY2024)  
│ │ [Excludes1: dementia with Parkinsonism (G31.83)]  
│ │ [Use additional code for dementia]  
│ │  
│ ├── G20.A — PD Without Dyskinesia ❌ Non-billable header  
│ │ ├── G20.A1 — Without dyskinesia, without fluctuations ✅ Billable  
│ │ │ [= Stable motor phase; no levodopa complications; PD NOS option]  
│ │ └── G20.A2 — Without dyskinesia, with fluctuations ✅ Billable  
│ │ [= Wearing-off/OFF present; no dyskinesia; advanced therapy threshold]  
│ │  
│ ├── G20.B — PD With Dyskinesia ❌ Non-billable header  
│ │ │ [Excludes1: drug induced dystonia (G24.0-)]  
│ │ ├── G20.B1 — With dyskinesia, without fluctuations ✅ Billable  
│ │ │ [= Dyskinesia only; no wearing-off; early LID stage]  
│ │ └── G20.B2 — With dyskinesia, WITH fluctuations ◀ THIS CODE ✅ Billable  
│ │ [= BOTH dyskinesia AND wearing-off/OFF — most advanced motor complication stage]  
│ │  
│ └── G20.C — Parkinsonism, unspecified ✅ Billable  
│ [Use ONLY when idiopathic vs. secondary undetermined]  
│  
├── G21 — Secondary Parkinsonism ← EXCLUDES1 from G20 — separate code family  
│ ├── G21.11 — Neuroleptic induced Parkinsonism ✅ Billable  
│ ├── G21.19 — Other drug induced secondary Parkinsonism ✅ Billable  
│ ├── G21.3 — Postencephalitic Parkinsonism ✅ Billable  
│ ├── G21.4 — Vascular Parkinsonism ✅ Billable  
│ ├── G21.8 — Other secondary Parkinsonism ✅ Billable  
│ └── G21.9 — Secondary Parkinsonism, unspecified ✅ Billable  
│  
└── G24 — Dystonia — Excludes1 from G20.B subcategory  
├── G24.01 — Drug induced subacute dyskinesia (tardive dyskinesia) ✅ Billable  
└── G24.02 — Drug induced acute dystonia ✅ Billable

G20.B2 is the Terminal G20 Motor Complication Code

G20.B2 is the most advanced motor complication subcode in the G20 family. There is no subcode beyond G20.B2 for worsening motor complications within the G20 structure. As motor complications progress at the G20.B2 stage, the clinical focus shifts from subcode upgrading to: (1) documenting advanced therapy utilization (DBS, LCIG, CSAI); (2) escalating comorbidity capture (dementia severity, aspiration, malnutrition, autonomic failure); and (3) transitioning documentation toward palliative and comfort care goals when appropriate.

---

✅ Includes

The following clinical terms and scenarios map to G20.B2 when idiopathic Parkinson’s disease is confirmed with BOTH explicitly documented dyskinesia AND documented motor fluctuations:

• Parkinson’s disease with levodopa-induced dyskinesia and wearing-off
• Parkinson’s disease with LID and motor fluctuations
• Parkinson’s disease with dyskinesia and OFF episodes
• Parkinson’s disease with dyskinesia and on-off phenomenon
• Advanced Parkinson’s disease with peak-dose dyskinesia and end-of-dose wearing-off
• Parkinson’s disease with dyskinesia and early-morning akinesia
• Parkinson’s disease with dyskinesia and unpredictable ON-OFF switching

Per AHA Coding Clinic Q1 2024 — Both Elements Require Explicit Documentation

Both components of G20.B2 require explicit physician documentation:

• “Tremor” does NOT satisfy the dyskinesia requirement — per Coding Clinic Q1 2024, G20.B codes require specific documentation of dyskinesia
• Absent documentation of wearing-off, OFF episodes, or fluctuations → use G20.B1 (dyskinesia only)
• Absent documentation of dyskinesia → use G20.A2 (fluctuations only)
• Both specifically documented → G20.B2

---

❌ Excludes

Excludes 1 — Cannot Be Coded Simultaneously with G20.B2

Code	Description	Note
G24.01	Drug induced subacute dyskinesia (tardive dyskinesia)	Excludes1 at the G20.B subcategory level — levodopa-induced dyskinesia in idiopathic PD (G20.B2) vs. neuroleptic-induced tardive dyskinesia (G24.01) are mutually exclusive; query physician for attribution when patient is on both levodopa and dopamine-blocking agents
G24.02	Drug induced acute dystonia	Excludes1 at G20.B subcategory level; mutually exclusive with G20.B2
G21.11	Neuroleptic induced Parkinsonism	Mutually exclusive with all G20 idiopathic PD codes
G21.19	Other drug induced secondary Parkinsonism	Mutually exclusive
G21.3	Postencephalitic Parkinsonism	Mutually exclusive
G21.4	Vascular Parkinsonism	Mutually exclusive — vascular parkinsonism cannot produce wearing-off (no dopaminergic terminal loss substrate)
G21.8	Other secondary Parkinsonism	Mutually exclusive
G21.9	Secondary Parkinsonism, unspecified	Mutually exclusive

G24.01 Excludes1 — Most Critical Compliance Boundary at G20.B2 Stage

At the G20.B2 advanced stage, patients are frequently on both levodopa AND antipsychotic agents (for PD psychosis — hallucinations, delusions) — creating a scenario where both levodopa-induced dyskinesia AND neuroleptic-induced tardive dyskinesia could theoretically coexist clinically. These codes are Excludes1 — mutually exclusive in ICD-10-CM. When a G20.B2-stage patient with documented LID is ALSO on quetiapine, clozapine, or another dopamine-blocking agent, and involuntary movements are present, the physician must attribute the dyskinesia (levodopa-induced = G20.B2 territory vs. drug-induced = G24.01). This clinical attribution query is among the most important CDI actions at the advanced PD stage.

Excludes 2 — May Be Coded in Addition if Separately Present

Code	Description	Note
G31.83	Dementia with Lewy bodies	Excludes 2 from G20 category — may be coded alongside G20.B2 if DLB is distinctly documented alongside established motor PD (1-year rule: PDD = dementia >1 year after motor onset; DLB = dementia within 1 year of motor onset); physician must document both diagnoses

Advanced PD Psychosis — Antipsychotic Selection is a Coding Alert

At the G20.B2 stage, PD psychosis (hallucinations, delusions) is common — documented as F02.82/F02.B2/F02.C2 (dementia with psychotic disturbance). Only clozapine and pimavanserin are FDA-approved for PD psychosis without worsening motor symptoms; most other antipsychotics block dopamine receptors, worsening Parkinsonism and creating Excludes1 conflict with G24.01. When clozapine or pimavanserin is documented as the antipsychotic agent, it supports that residual involuntary movements are levodopa-induced (G20.B2) rather than drug-induced (G24.01).

---

📋 Clinical Overview

G20.B2 — The Advanced PD Motor Stage Defined

The G20.B2 stage is clinically synonymous with what movement disorder specialists call “advanced Parkinson’s disease” from a motor motor complication perspective. The convergence of both dyskinesia and fluctuations signals that oral levodopa pharmacotherapy has reached its biological ceiling of therapeutic adequacy — dopaminergic terminal loss is so extensive that no oral regimen adjustment can simultaneously eliminate both OFF periods (requiring higher levodopa exposure) and dyskinesia (requiring lower levodopa exposure).

Feature	G20.A1	G20.A2	G20.B1	G20.B2
Dyskinesia	❌ Absent	❌ Absent	✅ Present	✅ Present
Fluctuations/OFF	❌ Absent	✅ Present	❌ Absent	✅ Present
Both complications	❌	❌	❌	✅ Both
Oral regimen adequate	✅ Usually	⚠️ Partial	⚠️ Partial	❌ Usually not
Advanced therapy need	Low	Moderate-High	Moderate-High	Highest
PDD prevalence	Lower	Moderate	Moderate	Highest
Aspiration risk	Lower	Moderate	Moderate	Highest
DBS/LCIG/CSAI indicated	Rarely	Often	Often	Most strongly

CDI Query Priority at G20.B2 — Both Complications Must Be Independently Documented

At a G20.B2 encounter, the highest-priority documentation action is confirming that BOTH complications appear distinctly documented in the record. If the physician documents only “Parkinson’s disease with motor complications” without specifying which type — a CDI query for “dyskinesia and/or wearing-off/OFF episodes?” is warranted. The distinction between G20.A2 (wearing-off only), G20.B1 (dyskinesia only), and G20.B2 (both) is clinically material and cannot be inferred by the coder.

Advanced Therapy Decision — G20.B2 as the Strongest Indication

All three major device-assisted advanced therapies for Parkinson’s disease are primarily indicated at the G20.B2 stage — when both complications coexist and cannot be adequately controlled with oral pharmacotherapy alone.

Advanced Therapy	Mechanism at G20.B2	Clinical Consideration
Deep Brain Stimulation (DBS) — STN or GPi	STN DBS reduces levodopa requirement → reduces LID; GPi DBS directly suppresses dyskinesia while maintaining ON time; both reduce OFF time	Most widely used; bilateral STN preferred when cognitive function intact; bilateral GPi preferred when dyskinesia is dominant and cognitive status is borderline; both significantly reduce motor fluctuations
Levodopa-Carbidopa Intestinal Gel (LCIG/CLES) — intrajejunal pump	Continuous intrajejunal levodopa delivery eliminates pulsatile pharmacokinetics → smooths plasma levodopa → reduces both dyskinesia and OFF time simultaneously	Requires PEG/J tube; avoids CNS surgery; well-suited for patients with cognitive impairment who may not be DBS candidates; FDA-approved for advanced PD with motor fluctuations
Continuous Subcutaneous Apomorphine Infusion (CSAI)	Continuous subcutaneous dopamine agonist → smooth, sustained receptor stimulation → reduces OFF time and may reduce dyskinesia	Phase 3 InfusON study (2025) demonstrated efficacy for motor fluctuations in US patients; avoids CNS surgery and J-tube; newer availability in the US market

Pathophysiology

At the G20.B2 stage, the remaining dopaminergic nigrostriatal terminals have been so severely depleted that exogenous levodopa’s plasma kinetics are translated almost directly — without buffering — into striatal dopamine concentrations that oscillate dramatically between doses. This creates a pharmacological paradox: increasing levodopa doses to prevent OFF periods pushes striatal dopamine above the dyskinesia threshold; reducing doses to suppress dyskinesia allows plasma levels to fall below the therapeutic threshold, producing OFF periods. Striatal D1 receptor hypersensitization (accumulation of deltaFosB, aberrant ERK signaling, abnormal striatal output via the direct pathway) drives peak-dose LID while simultaneously the indirect pathway’s insufficient suppression drives OFF-period bradykinesia and rigidity. Continuous dopaminergic stimulation — via DBS modulation of pathological GPi/STN output, or via LCIG/CSAI continuous delivery — breaks both pharmacological traps simultaneously, providing stable ON time without the peaks and troughs of oral therapy.

Documentation Requirements

For accurate assignment of G20.B2, physician documentation must explicitly include:

1. Explicit Parkinson’s disease diagnosis — “Parkinson’s disease” or “idiopathic PD” confirmed by the treating neurologist
2. Explicit dyskinesia documentation — “dyskinesia,” “levodopa-induced dyskinesia,” “LID,” “involuntary movements,” “choreiform movements” — NOT “tremor” alone (per AHA Coding Clinic Q1 2024)
3. Explicit fluctuation documentation — “wearing-off,” “OFF episodes,” “on-off phenomenon,” “motor fluctuations,” “end-of-dose deterioration” (per March 2026 Coding Clinic, “OFF episodes” cross-references to the fluctuations concept)
4. Confirmation of idiopathic etiology — excludes secondary parkinsonism and drug-induced causes
5. Attribution clarity — when patient is on antipsychotic agents, dyskinesia attribution (levodopa-induced vs. drug-induced) must be clinically established before G20.B2 is assigned (vs. G24.01)
6. Advanced therapy status — document DBS presence, LCIG/CLES pump, CSAI pump, or prior advanced therapy; essential for device management CPT medical necessity
7. Dementia status — severity and behavioral disturbance type for mandatory F02.x code pair when dementia present

---

💰 HCC Risk Adjustment (CMS-HCC v28)

Field	Detail
CMS-HCC Model Version	v28 (100% Implementation FY2026)
HCC Assignment	✅ Mapped — HCC 155
HCC Category Name	Parkinson’s Disease and Huntington’s Disease
RAF Coefficient (Community Non-Dual Aged)	~0.372
G20 Subcode Differentiation	G20.B2 maps to same HCC 155 as G20.A1/A2/B1 — motor complication subcode does not differentiate HCC tier
RxHCC Assignment	Review current RxHCC mapping tables

G20.B2 maps to CMS-HCC v28 HCC 155, the same tier as all other G20 subcodes. While the base HCC RAF is identical, the G20.B2 stage carries the highest density of stacked RAF-bearing comorbidities of any G20 subcode — making complete comorbidity capture far more impactful than the base HCC 155 alone.

G20.B2 = Highest Compound HCC Opportunity in the G20 Family

The advanced disease stage of G20.B2 substantially increases the probability of ALL of the following HCC-bearing comorbidities being present and codeable at the same encounter:

• Severe Parkinson’s disease dementia (F02.C0 / F02.C1 / F02.C2) → HCC 125 (highest dementia tier); query for severity and disturbance type at every G20.B2 encounter — this is the single highest-impact CDI action
• Moderate PDD (F02.B0 etc.) → HCC 126
• Major depressive disorder (F32.9, F33.9) → review HCC mapping
• Dysphagia (R13.19) → critical safety code; review HCC mapping
• Aspiration pneumonia (J69.0) → MCC for DRG; review HCC mapping
• Severe protein-calorie malnutrition (E43) → review HCC mapping; constant dyskinesia produces massive caloric expenditure
• Autonomic failure / orthostatic hypotension (G90.3) → review HCC mapping
• Heart failure (I50.9) — check for coexistent CV disease in elderly PD patients

At a G20.B2 encounter, the clinical picture routinely justifies 6-12 active diagnoses. Every condition meeting UHDDS “other diagnoses” criteria must be reported.

---

🏥 MS-DRG Assignment

MDC 01 — Diseases and Disorders of the Nervous System

DRG	Title	Est. Relative Weight*
DRG 056	Degenerative Nervous System Disorders with MCC	~2.23
DRG 057	Degenerative Nervous System Disorders without MCC	~1.30

*Approximate. Verify against IPPS FY2026 Final Rule tables. Degenerative nervous system disorders have only two DRGs — DRG 056 (MCC) and DRG 057 (no MCC); there is no DRG 058.

G20.B2 Should Frequently Group to DRG 056 When Coded Completely

At the G20.B2 stage — when all clinically present and documented comorbidities are fully coded — the case should frequently qualify for DRG 056 (with MCC). The most common MCC pathways at G20.B2 include:

• F02.C0 or F02.C1 (severe dementia) → MCC → DRG 056
• J69.0 (aspiration pneumonia) → MCC → DRG 056
• J96.01 (acute respiratory failure with hypoxia) → MCC → DRG 056
• A41.9 (sepsis) → MCC → DRG 056
• E43 (unspecified severe protein-calorie malnutrition) → review MCC status

A G20.B2 inpatient case that groups only to DRG 057 — without any of these comorbidities coded — is a CDI audit red flag at this disease stage. These comorbidities are clinically expected and almost invariably present in advanced PD hospitalizations; their absence in the coding suggests documentation and CDI gaps rather than their clinical absence.

---

🔗 Related ICD-10-CM Codes

G20 Full Motor Complication Matrix

Code	Description	Motor Stage
G20.A1	Without dyskinesia, without mention of fluctuations	Stable; no motor complications
G20.A2	Without dyskinesia, with fluctuations	Wearing-off present; no dyskinesia
G20.B1	With dyskinesia, without mention of fluctuations	Dyskinesia only; no wearing-off
G20.B2	With dyskinesia, with fluctuations ← This Code	Both complications — most advanced stage
G20.C1	Parkinsonism, unspecified	Only when idiopathic vs. secondary undetermined

Drug-Induced Dystonia — Excludes1 from G20.B

Code	Description
G24.01	Drug induced subacute dyskinesia (tardive dyskinesia — Excludes1 from G20.B; mutually exclusive with G20.B2)
G24.02	Drug induced acute dystonia (Excludes1 from G20.B)

Mandatory Associated Codes — Dementia (Use Additional Code per Tabular Instruction)

Code	Description	HCC v28
F02.80	Dementia in other diseases, unspecified severity, without disturbance	HCC 127
F02.B0	Dementia in other diseases, moderate, without disturbance	HCC 126
F02.C0	Dementia in other diseases, severe, without disturbance	HCC 125
F02.B1	Dementia in other diseases, moderate, with behavioral disturbance	HCC 126
F02.C1	Dementia in other diseases, severe, with behavioral disturbance	HCC 125
F02.B2	Dementia in other diseases, moderate, with psychotic disturbance	HCC 126
F02.C2	Dementia in other diseases, severe, with psychotic disturbance	HCC 125

Common High-Priority Comorbidity Codes at the G20.B2 Stage

Code	Description	Coding Relevance
J69.0	Pneumonitis due to inhalation of food and vomit (aspiration pneumonia)	MCC; leading cause of death in advanced PD; highly prevalent at G20.B2 stage due to progressive oropharyngeal dysphagia
R13.19	Other dysphagia	Parkinson’s-related oropharyngeal dysphagia — drives aspiration precautions, SLP consult, G-tube discussions; code whenever documented
E43	Unspecified severe protein-calorie malnutrition	Constant dyskinesia produces massive caloric expenditure; dysphagia reduces intake; malnutrition is both clinically serious and an important quality/reimbursement code at G20.B2
E44.0	Moderate protein-calorie malnutrition	Code based on physician documentation of severity
G90.3	Multi-system degeneration of the autonomic nervous system	Autonomic failure is most severe at G20.B2 stage — orthostatic hypotension, neurogenic bladder, constipation, hyperhidrosis during ON phase
G47.52	REM sleep behavior disorder	Prevalent PD comorbidity; often associated with dementia and advanced disease
F32.9	Major depressive disorder, single episode, unspecified	Neuropsychiatric comorbidity; depression and anxiety frequently cycle with motor ON-OFF at G20.B2 stage
Z96.82	Presence of neurostimulator	Code when DBS is already implanted — supports programming CPT medical necessity
W19.XXXA	Unspecified fall, initial encounter	Falls are most frequent and most injurious at G20.B2 — OFF-period freezing and dyskinesia-related loss of postural control both contribute
Z87.39	Personal history of metabolic disease	Applicable if previously resolved metabolic contributor remains relevant to history

---

🛠️ Commonly Associated CPT Codes (Neurology)

Outpatient and Physician Setting Context

The CPT codes below are associated with the evaluation, management, and advanced therapy treatment of Parkinson’s disease with both dyskinesia and fluctuations in outpatient and physician fee schedule settings. In the inpatient setting, ICD-10-PCS procedure codes govern procedural reporting.

CPT Code	Description	Clinical Application
99215	Office or other outpatient visit, established patient, high MDC	Standard visit for G20.B2 advanced PD management — complex polypharmacy adjustment, advanced therapy counseling (DBS, LCIG, CSAI), caregiver burden assessment, multiple comorbidity management; high MDC almost always justified at this stage
99483	Cognitive assessment and care plan services	Formal cognitive assessment — PDD prevalence is highest at G20.B2; all 9 elements required; modifier -25 required if same DOS as E/M
96132	Neuropsychological testing evaluation; first hour	DBS candidacy evaluation — neuropsychological battery is a standard prerequisite for DBS surgical candidacy; cognitive status is the primary exclusion criterion for DBS at G20.B2 stage
96133	+Neuropsychological testing evaluation; each additional hour	Add-on; never alone
96116	Neurobehavioral status exam; first hour	Office-based cognitive screen — active dementia surveillance at G20.B2 stage; MoCA, MMSE, MDS-UPDRS Part I
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter (DBS), programming; first 15 minutes	DBS programming for G20.B2 patients — parameter optimization to simultaneously reduce dyskinesia and OFF time; the most frequent advanced procedure at this stage for DBS-implanted patients
95984	+Electronic analysis of implanted neurostimulator pulse generator/transmitter (DBS), programming; each additional 15 minutes	Add-on for additional DBS programming time; never alone
61885	Insertion or replacement of cranial neurostimulator pulse generator; single electrode array	DBS IPG implantation or battery replacement — G20.B2 (both dyskinesia AND fluctuations) is the strongest ICD-10-CM support code for DBS medical necessity
61886	Insertion or replacement of cranial neurostimulator pulse generator; two or more electrode arrays	Bilateral DBS IPG — most common configuration for advanced PD; bilateral STN or bilateral GPi depending on clinical profile
96365	Intravenous infusion for therapy; initial, up to 1 hour	Infusion administration for LCIG/CLES or CSAI (subcutaneous apomorphine infusion) in clinic/outpatient settings when administered by qualified healthcare personnel
96366	+Intravenous infusion; each additional hour	Add-on for additional infusion time; never alone

NCCI Bundling Considerations

NCCI PTP Edits — Verify Before Billing

• 95983 and 95984 are bundled into DBS surgical codes (61885/61886) on the same DOS — do NOT report programming on the same day as DBS implantation.
• 99215 and 95983/95984 same DOS: modifier -25 required on the E/M when separately identifiable from the programming visit.
• 99483 and standard E/M same DOS: modifier -25 required on the E/M.
• 96132 (neuropsychological testing) and 95983 (DBS programming) same DOS: verify NCCI PTP edit status; each service must be independently performed and medically necessary.
• 61885/61886 (IPG surgery) and 95983 same DOS: bundled — do NOT report programming on the surgical day.
• G20.B2 documentation supports the highest-tier DBS medical necessity among all G20 subcodes; ensure it is consistently and specifically documented in the record supporting every DBS-related prior authorization and procedure note.

---

🔬 ICD-10-PCS Crosswalk (Inpatient Procedures)

When G20.B2 is an inpatient diagnosis and a surgical or therapeutic procedure is performed, the following ICD-10-PCS sections and root operations are relevant.

PCS Section	Body System	Root Operation	Clinical Application
0 (Medical & Surgical)	0 (Central Nervous System)	H (Insertion)	00H00MZ — DBS lead placement (open approach, brain); bilateral STN or GPi targeting at G20.B2; both targets effectively reduce combined dyskinesia + fluctuations
0 (Medical & Surgical)	J (Subcutaneous Tissue)	H (Insertion)	0JH60MZ — DBS IPG implantation (chest subcutaneous tissue and fascia)
0 (Medical & Surgical)	D (Gastrointestinal)	H (Insertion)	0DH64UZ — PEG/J tube insertion for LCIG/CLES intrajejunal infusion access; appropriate for G20.B2 patients who are not DBS candidates (cognitive impairment, surgical risk)
0 (Medical & Surgical)	J (Subcutaneous Tissue)	H (Insertion)	Subcutaneous catheter/pump insertion for CSAI (continuous subcutaneous apomorphine infusion)
0 (Medical & Surgical)	0 (Central Nervous System)	W (Revision)	DBS lead revision or IPG replacement — revision root operation
G (Mental Health)	Z (None)	3 (Psychological Tests)	GZ3ZZZZ — Neuropsychological testing (DBS candidacy evaluation in inpatient setting)

---

💊 Coding Scenarios and Examples

---

Scenario 1 — Advanced PD With Dyskinesia and Wearing-Off, DBS Candidacy (Outpatient)

Clinical Vignette: A 65-year-old male with 8-year history of PD presents reporting both involuntary wiggling movements at peak levodopa (dyskinesia for 2-3 hours post-dose) AND wearing-off with tremor and stiffness returning 45 minutes before each dose. No adequate medication regimen adjustment has controlled both. Neurologist documents: “Parkinson’s disease with levodopa-induced dyskinesia and wearing-off.” DBS evaluation initiated; neuropsychological battery ordered.

CPT Codes:

• 99215 — Office visit, established patient, high MDC (DBS candidacy evaluation, advanced therapy counseling); append modifier -25
• 96132 — Neuropsychological testing evaluation, first hour

ICD-10-CM:

• G20.B2 — Parkinson’s disease with dyskinesia, with fluctuations

G20.B2 is the Strongest DBS Medical Necessity Code

When G20.B2 is present in the record, both primary DBS indications — dyskinesia AND motor fluctuations — are simultaneously documented. This is the most robust ICD-10-CM support for DBS prior authorization among all G20 subcodes and should be consistently present in all DBS candidacy evaluation notes.

---

Scenario 2 — Advanced PD With Both Complications, LCIG Initiation (Inpatient)

Clinical Vignette: A 73-year-old female with advanced Parkinson’s disease with dyskinesia and motor fluctuations (G20.B2) who is NOT a DBS surgical candidate (moderate dementia) is admitted for levodopa-carbidopa intestinal gel (LCIG) pump initiation via PEG/J tube. No aspiration pneumonia. Moderate PDD with behavioral disturbance documented.

Principal Diagnosis:

• G20.B2 — Parkinson’s disease with dyskinesia, with fluctuations

Additional Diagnoses:

• F02.B1 — Dementia in other diseases, moderate, with behavioral disturbance (mandatory F02.x pair; moderate = CC; verify CC/MCC table)
• R13.19 — Other dysphagia (relevant; LCIG via J-tube also addresses dysphagia-related oral intake issues)

ICD-10-PCS:

• 0DH64UZ — Insertion of Feeding Device into Stomach, PEA (PEG/J tube for LCIG delivery)

LCIG Indicated When DBS Is Not an Option

At the G20.B2 stage, DBS candidacy requires intact cognitive function. When F02.B0-F02.C4 dementia is present alongside G20.B2, DBS may be excluded — and LCIG or CSAI becomes the appropriate advanced therapy. Always document the reason DBS was not selected (cognitive impairment, surgical risk, patient preference) to support LCIG/CSAI medical necessity.

---

Scenario 3 — Advanced PD, Aspiration Pneumonia, DRG 056 (Inpatient)

Clinical Vignette: A 79-year-old male with Parkinson’s disease with dyskinesia and motor fluctuations is admitted with aspiration pneumonia secondary to progressive dysphagia. He has severe dementia (Parkinson’s disease dementia, severe severity, with behavioral disturbance). No DBS in place.

Principal Diagnosis:

• G20.B2 — Parkinson’s disease with dyskinesia, with fluctuations (etiology — sequences first)

Additional Diagnoses:

• F02.C1 — Dementia in other diseases, severe, with behavioral disturbance (MCC)
• J69.0 — Pneumonitis due to inhalation of food and vomit (MCC)
• R13.19 — Other dysphagia (supporting comorbidity)
• E43 — Unspecified severe protein-calorie malnutrition (if documented; review MCC status)

MS-DRG Assignment:

• DRG 056 — Degenerative Nervous System Disorders with MCC (multiple MCCs present)

This Is the G20.B2 DRG 056 Clinical Profile

The combination of G20.B2 + F02.C1 + J69.0 + R13.19 is the archetypal advanced PD inpatient case that should routinely group to DRG 056. If this profile groups to DRG 057 on any case, it signals a documentation gap — specifically, the severe dementia (F02.Cx) and/or aspiration pneumonia (J69.0) are likely absent from the documentation or undercoded.

---

Scenario 4 — G20.B2 With DBS, Ongoing Motor Complication Management (Outpatient)

Clinical Vignette: A 69-year-old female with Parkinson’s disease with dyskinesia and fluctuations, status post bilateral STN DBS implantation 18 months ago, presents for routine programming and follow-up. Despite DBS, residual wearing-off and mild dyskinesia persist — both documented. DBS programming takes 30 minutes. Separately identifiable E/M performed.

CPT Codes:

• 99214 — Office visit, established patient, moderate MDC; append modifier -25
• 95983 — DBS programming, first 15 minutes
• 95984 — +DBS programming, additional 15 minutes (×1)

ICD-10-CM:

• G20.B2 — Parkinson’s disease with dyskinesia, with fluctuations (both complications persist despite DBS)
• Z96.82 — Presence of neurostimulator (existing DBS device)

G20.B2 May Persist After DBS Implantation

DBS significantly reduces but does not always completely eliminate dyskinesia and fluctuations in all patients. If both complications persist post-DBS and are documented, G20.B2 remains the correct code — the subcode reflects the current clinical state, not the intended outcome. Code Z96.82 additionally to document device presence.

---

⚠️ Coding Pitfalls and Tips

	Pitfall or Tip
❌	Never assign G20.B2 based on “tremor” documentation alone — per AHA Coding Clinic Q1 2024, G20.B codes require explicit physician documentation of dyskinesia; rest tremor is a cardinal PD motor symptom that does NOT satisfy the G20.B requirement
❌	Do not assign G20.B2 if only one complication is documented — dyskinesia only → G20.B1; wearing-off/OFF only → G20.A2; G20.B2 requires both explicitly documented
❌	Do not submit the retired bare G20 code — non-billable since FY2024; always use a 5-character G20 subcode
❌	Do not assign G20.B2 for drug-induced parkinsonism — G21.x codes are Excludes1 from all G20 codes; drug-induced parkinsonism is never coded to G20.B2
❌	Do not confuse levodopa-induced dyskinesia with tardive dyskinesia — LID in PD = G20.B2 territory; neuroleptic-induced tardive dyskinesia = G24.01; mutually exclusive (Excludes1 at G20.B subcategory level); query physician for attribution when patient is on both levodopa and antipsychotics
❌	Do not sequence F02.x as principal — Parkinson’s dementia codes are mandatory manifestation codes; G20.B2 always sequences first
❌	Do not omit F02.x when PDD is documented — “Use additional code” instruction is mandatory; missing dementia pair loses HCC 125/126/127 capture
✅	Always query both axes — “Is dyskinesia present?” AND “Is wearing-off/are OFF episodes present?” — both must be explicitly documented for G20.B2
✅	Query for dementia severity at every G20.B2 encounter — PDD at severe stage (F02.Cx) is both MCC and HCC 125; this is the highest-value CDI action at every G20.B2 inpatient encounter
✅	G20.B2 is the strongest advanced therapy support code — for DBS, LCIG/CLES, and CSAI prior authorizations; ensure it is in the record before any advanced therapy submission
✅	Code J69.0 when aspiration pneumonia is documented — MCC; critical safety and reimbursement code; particularly prevalent at G20.B2 stage
✅	Code R13.19 whenever dysphagia is documented — drives SLP consult, diet modification, aspiration precaution coding; does NOT require aspiration event to be coded
✅	Code E43 / E44.0 for malnutrition when documented — constant dyskinesia creates significant caloric expenditure; query for nutritional status assessment and malnutrition documentation at every G20.B2 inpatient encounter
✅	Code Z96.82 (presence of neurostimulator) when DBS is implanted — supports all DBS programming CPT codes and device management documentation
✅	DRG 056 should be the expected grouping at G20.B2 when the clinical picture is completely captured — a DRG 057 assignment at this disease stage is a CDI audit flag
✅	Document antipsychotic agent when used for PD psychosis — clozapine or pimavanserin supports G20.B2 attribution vs. G24.01; document medication name in assessment/plan to support attribution clarity

---

📚 Sources

1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. Tabular List — G20.B2; G20.B subcategory Excludes1 (drug induced dystonia G24.0-); Use additional code instructions; Etiology/Manifestation Convention (Section I.B.13).

2. AHA Coding Clinic. Q1 2024 — Parkinson’s Disease: Dyskinesia vs. Tremor. Official guidance: G20.B codes require explicit physician documentation of dyskinesia; tremor does not satisfy G20.B coding.

3. AHA Coding Clinic (via medlearn.com). Coding Update: An Index Change for Parkinson’s Disease. March 2026. Alphabetic Index cross-reference: OFF episodes → G20.A2 (no dyskinesia) or G20.B2 (with dyskinesia) per fluctuation component.

4. AAPC. ICD-10 Code for Parkinson’s Disease With Dyskinesia, With Fluctuations (G20.B2). Tabular structure and clinical annotations.

5. UASI Solutions. Parkinson’s Disease Tremor vs. Dyskinesia Coding. April 2025. AHA Coding Clinic Q1 2024 guidance summary.

6. PMC/NIH. Treatment of Advanced Parkinson’s Disease. PMC4140171. Advanced therapy indications for G20.B2-stage disease.

7. PubMed. Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Results from Phase 3 InfusON Study. PubMed 39973510. March 2025. CSAI efficacy for G20.B2-stage motor fluctuations in US patients.

8. Enclarapharmacia / Advanced Parkinson’s Disease Considerations for Patient Management. September 2025. Advanced PD stage management overview.

9. CMS. 2026 Medicare Advantage CMS-HCC Model v28 — Final Risk Adjustment Coefficients. HCC 155 (Parkinson’s Disease and Huntington’s Disease).

10. CMS. IPPS Final Rule FY2026 — MS-DRG Definitions Manual v43. MDC 01; DRG 056/057.

11. Boston Scientific. Deep Brain Stimulation 2026 Reimbursement Guide. G20.B2 medical necessity for DBS; bilateral STN/GPi CPT codes.

12. AMA. CPT Professional Edition 2026. Neurology; DBS programming; infusion administration.

13. CMS. NCCI Policy Manual for Medicare Services, current version.